SCHEMBL3675294

SCHEMBL3675294

Cc1ccc(C(=O)N2CCN(c3ccc(C(=O)NCCCN(C)C)cn3)CC2)c(C)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.56
HTT P42858 2/20 0.56
LMNA P02545 2/20 0.56
KDM4E B2RXH2 1/20 0.56
SCD O00767 2/20 0.50
EGLN1 Q9GZT9 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
POLB P06746 1/20 0.45
ALOX15 P16050 1/20 0.45
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
FOLH1 Q04609 1/20 0.43
MAPT P10636 1/20 0.42
TSHR P16473 1/20 0.42
NAMPT P43490 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3673516 0.90 LMNA (0.59) SMN1; SMN2HTTLMNAKDM4ESCD
SCHEMBL3670642 0.89 LMNA (0.58) SMN1; SMN2HTTLMNAKDM4ESCD
SCHEMBL3671418 0.88 KDM4E (0.57) SMN1; SMN2HTTLMNAKDM4ESCD
SCHEMBL3676764 0.88 LMNA (0.57) SMN1; SMN2HTTLMNAKDM4ESCD
SCHEMBL3674361 0.86 SMN1; SMN2 (0.55) SMN1; SMN2HTTLMNAKDM4ESCD
SCHEMBL3674465 0.86 SCD (0.49) SMN1; SMN2SCDEGLN1NPC1RAB9A
SCHEMBL3674461 0.86 LMNA (0.55) SMN1; SMN2HTTLMNAKDM4ESCD
SCHEMBL3670254 0.86 SCD (0.62) SMN1; SMN2HTTLMNAKDM4ESCD
SCHEMBL3672273 0.85 LMNA (0.54) SMN1; SMN2HTTLMNAKDM4ESCD
SCHEMBL3679019 0.85 SCD (0.61) SMN1; SMN2HTTLMNAKDM4ESCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP claimed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US claimed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US claimed
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP disclosed
EP-2266566-A2 Nicotinamide derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. (CA) 2010-12-29 EP disclosed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US disclosed
US-20070087363-A1 Therapeutic methods, compounds and compositions MYRIAD GENETICS, INCORPORATED (US) 2007-04-19 US disclosed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents NAMPT, NNT, NNMT SMN1; SMN2 112/4885HTT 1288/4885LMNA 175/4885
US-20070087363-A1 Therapeutic methods, compounds and compositions APP, BACE1, PSEN1 SMN1; SMN2 123/4885HTT 8/4885LMNA 369/4885
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS NAMPT, NNT, NNMT SMN1; SMN2 112/4885HTT 1288/4885LMNA 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.